CHICAGO-- MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage company focusing on telomere-targeting cancer immunotherapies, has announced its participation in the BIO International Convention from June 3-6, 2024, in San Diego, California. This convention is recognized as the largest and most inclusive event for the biotechnology sector, attracting over 20,000 industry professionals worldwide.
Vlad Vitoc, M.D., the Chairman and CEO of MAIA, will present the latest findings from the company's Phase 2 THIO-101 clinical trial, which explores the efficacy of THIO when used in sequence with the immune checkpoint inhibitor cemiplimab (Libtayo®) for advanced non-small cell lung cancer (NSCLC). Scheduled for Wednesday, June 5, at 11:30 a.m. PDT in Company Presentation Theater 1, located in Hall A of the San Diego Convention Center, Dr. Vitoc's presentation will highlight the breakthrough potential of THIO. Throughout the three-day event, Dr. Vitoc and his team will also engage in meetings with pharmaceutical executives, researchers, and other key stakeholders.
BIO, the Biotechnology Innovation Organization, is the largest advocacy association globally for biotechnology companies, academic and research institutions, state biotech centers, and similar organizations across more than 30 countries. Its mission is to drive the progress of biotechnology innovations that address major challenges across health, agriculture, and environment.
THIO, or 6-thio-2’-deoxyguanosine, is an innovative investigational telomere-targeting agent undergoing clinical trials for its effectiveness against NSCLC. Telomeres and the enzyme telomerase are key factors in the survival and resistance of cancer cells to current treatments. THIO works by modifying telomeric DNA structure, causing DNA damage responses, and inducing selective cancer cell death. This damage prompts the accumulation of telomeric fragments in cytosolic micronuclei, activating both innate and adaptive immune responses. Sequential treatment with THIO followed by PD-(L)1 inhibitors has shown significant and lasting tumor regression in advanced cancer models by inducing cancer-specific immune memory. THIO is being developed as a second-line treatment for NSCLC patients who have not responded to existing checkpoint inhibitors.
THIO-101 is a multicenter, open-label, dose-finding Phase 2 clinical trial that stands out as the first to assess the anti-tumor activity of THIO followed by PD-(L)1 inhibition. The trial's primary objectives are to assess the safety and tolerability of THIO as an anticancer agent and a priming immune activator, and to evaluate its clinical efficacy using Overall Response Rate (ORR) as the principal criterion. Preliminary results have shown that the treatment regimen of cemiplimab (Libtayo®) followed by THIO has been generally well-tolerated in a heavily pre-treated patient population. More information about this trial can be found on ClinicalTrials.gov under the identifier NCT05208944.
MAIA Biotechnology, Inc. is a company devoted to developing and commercializing potential first-in-class cancer therapies with novel mechanisms of action. Their leading program, THIO, targets telomeres in telomerase-positive cancer cells and is currently in clinical trials for treating NSCLC. MAIA’s mission is to create transformative treatments that significantly improve and extend the lives of cancer patients.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!